Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 01 Mar 2021
Proposal to fully fund Mercilon 28 for oral contraception
26 February 2021 - PHARMAC is seeking feedback on a proposal to increase the subsidy to fully fund ethinyloestradiol 20 ...
Posted by Michael Wonder on 01 Mar 2021
Johnson & Johnson COVID-19 vaccine authorised by U.S. FDA for emergency use - first single shot vaccine in fight against global pandemic
27 February 2021 - Johnson & Johnson today announced that the U.S. FDA has issued emergency use authorisation for its single-dose ...
Posted by Michael Wonder on 01 Mar 2021
Health Canada approves AstraZeneca's COVID-19 vaccine
26 February 2021 - Canada's regulator estimates vaccine's efficacy at 62.1 per cent. ...
Posted by Michael Wonder on 01 Mar 2021
Expanding access to life changing medicines for thousands of Australians
1 March 2021 - How many typos can you spot? I have clocked three. ...
Posted by Michael Wonder on 28 Feb 2021
Schedule of Pharmaceutical Benefits - 1 March 2021
1 March 2021 - The March 2021 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 28 Feb 2021
EMA accepts marketing application for somatrogon to treat paediatric patients with growth hormone deficiency
26 February 2021 - If approved, somatrogon will serve as a once-weekly treatment option. ...
Posted by Michael Wonder on 28 Feb 2021
The first doses of the Oxford-AstraZeneca COVID vaccine have arrived. What happens next?
28 February 2021 - Australia has doubled its coronavirus vaccine stocks after hundreds of thousands of doses of the Oxford-AstraZeneca ...
Posted by Michael Wonder on 28 Feb 2021
Eczema medicine Dupixent added to Pharmaceutical Benefits Scheme
26 February 2021 - Eczema has a significant effect on sufferers’ physical and mental wellbeing, but the new listing of a ...
Posted by Michael Wonder on 28 Feb 2021
New Zealand Pharmaceutical Schedule - 1 March 2021
1 March 2021 - The March 2021 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 28 Feb 2021
GSK receives CHMP positive opinion recommending approval of dostarlimab for women with recurrent or advanced endometrial cancer
26 February 2021 - GlaxoSmithKline today announced the CHMP of the EMA has adopted a positive opinion recommending dostarlimab, an anti-programmed ...
Posted by Michael Wonder on 27 Feb 2021
FDA issues emergency use authorisation for third COVID-19 vaccine
27 February 2021 - Action advances fight against COVID-19, follows comprehensive evaluation of available safety, effectiveness and manufacturing quality information by ...
Posted by Michael Wonder on 27 Feb 2021
FDA approves first treatment for molybdenum cofactor deficiency type A
26 February 2021 - Today, the U.S. FDA approved Nulibry (fosdenopterin) for injection to reduce the risk of death due to ...
Posted by Michael Wonder on 26 Feb 2021
Roche receives positive CHMP opinion for Evrysdi, the first and only at home spinal muscular atrophy treatment with proven efficacy in adults, children and infants two months and older
26 February 2021 - Evrysdi is approved in seven countries, submitted in 30 more. ...
Posted by Michael Wonder on 26 Feb 2021
FDA authorises marketing of novel device to help protect athletes’ brains during head impacts
26 February 2021 - Today, the U.S. FDA authorised marketing of a new device intended to be worn around the neck ...
Posted by Michael Wonder on 26 Feb 2021
Thousands of breast cancer patients to have routine access to NICE-approved drug combination
26 February 2021 - Another potentially life-extending drug combination for some people with advanced breast cancer will now be available for ...